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ABSTRACT
Background
Malaria is a preventable and treatable disease that is a major burden in the African sub-region, 
accounting for 75% of malaria related deaths globally. Prior to December 2009, quinine has been 
the therapeutic option of choice for the management of Malaria in our unit. In the non-intensive 
care unit setting a mortality benefit of artesunate over quinine has been shown by two major 
trials and thus artesunate is currently therapy of choice for severe malaria. There is paucity of 
South African data regarding the outcomes of severe malaria patients treated w ith quinine 
compared to those treated with artesunate in the intensive care unit (ICU).
Objectives
The aim of this study was to compare the outcomes of patients treated with artesunate versus 
those treated with quinine, over a four-year period in our ICU. The primary outcome variables 
were length of stay and mortality, secondary outcomes where hypoglycaemia episodes and 
neurological outcome as measured by GCS on admission and on discharge.
Methods
This was a retrospective cohort study of patients with severe malaria treated at Chris Hani 
Baragwanath Academic Hospital with artesunate or quinine. The study was done in an ICU 
setting. This included a review of patients treated in the unit from 1st January of 2008 to 31st 
December 2012. A p value of<0.05 was chosen as a measure of statistical significance.
V
Results
The sample consisted of 92 patients. Forty three percent (n=40) received quinine and 57% (n = 
52) received artesunate. There was no statistically significant difference between the two drugs 
in the treatment of severe malaria in our ICU with regards to length of stay (p=0.738), mortality 
(p=0.246), hypoglycaemia (p= 0.246) and neurological outcome as measured by GCS on 
admission and discharge (p= 0.357).
Conclusion
In our intensive care population the difference in outcomes between artesunate and quinine were 
not statistically significant. Artesunate did not confer an obvious benefit over quinine. 
Considering the differences in cost, logistical differences associated with the use of the two drugs 
as well as the emergence of artesunate resistance, we suggest that outcomes of artesunate versus 
quinine be investigated in other non-endemic regions.
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CHAPTER 1: PROTOCOLAND EXTENDED LITERATURE REVIEW
1.1 INTRODUCTION AND BACKGROUND
Malaria is a preventable and treatable disease that is a major burden worldwide and on the 
African continent. It is a protozoan infection, transmitted to humans by a blood-sucking female 
mosquito. There is a high prevalence of the disease in the tropical regions of the world such as 
Africa and Asia. The malaria pandemic continues in Sub-Saharan Africa, with increasing hospital 
admission statistics, despite great initiatives in disease prevention. In 2012, about 207 million 
cases were reported worldwide; the majority of which were in the Sub-Saharan region. The HIV 
pandemic in Sub-Saharan Africa adds to the overall disease burden, and poses a great risk of 
contracting severe form of malaria, especially for those that are non-immune.1"2
South Africa (SA) is noted as a low transmission area.1 Transmission is usually in the rainy 
season, between October and May, with the spread of malaria being increased by travelers and 
migrant labour from neighbouring Sub-Saharan states. The provinces most affected are Limpopo, 
Mpumalanga and Kwazulu- Natal, although there has been a slight increase in the number of 
reported cases in the province of Gauteng.3
Malaria fevers have been described as early as 850 BC, by the early Greeks, and later on in 400 
BC by Hippocrates. Hippocrates first observed patients with poor health, malaria fevers and 
enlarged spleens living in low lying wet areas.4
The search for the organism that caused malaria was only intensified in the 19th century' by a 
French physician Alphonse Laveran, who then discovered the parasite in blood, also implicating 
mosquitos as vectors. At that stage, he could not describe how the disease was transmitted to 
humans. Only in the 1890s, did Ronald Ross discover an association between mosquitoes and 
birds infected by Plasmodium Relictum. This disease was termed avian malaria.
A hundred years later, Italian scientists finally confirmed the link between human malaria and 
mosquitoes.4"5
Malaria reached epidemic proportions in Africa around the 1990s resulting in the launch of the 
new global strategy in the year 2000.6 Since then, the parasites causing malaria were identified as 
the Plasmodium species with many subtypes. The most common plasmodium species in the 
African continent, responsible for severe malaria is Plasmodium falciparum (P. falciparum). 
Plasmodium vivax also has the ability to cause severe malaria but is usually found in countries 
outside Sub-Saharan Africa.7
Non-communicable diseases such as ischaemic heart disease and stroke are the leading cause of 
death globally but in low income countries infectious diseases remain the leading cause of death. 
Sub-Saharan Africa carries a high burden of malaria related deaths, accounting for about 75% of 
deaths globally.7 According to the global burden of disease report in 2004, malaria was number 
fourteen amongst the top leading twenty most frequent cause of death in the world. In low 
income countries, such as the African region, malaria was part of the top ten leading causes of 
death.8 According to the World Health Organization (WHO), the malaria incidence has decreased 
by twenty nine percent globally between the period of 2010 and 2015. The global technical
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strategy for malaria 2016-2030 aims to decrease the malaria incidence and mortality rates by at 
least 90 percent in 2030.9
1.2 LIFE CYCLE OF MALARIA
Only five species in the genus Plasmodium are known to cause infections in humans, namely 
Plasmodium malariae, Plasmodium vivax, Plasmodium ovale, Plasmodium knowlesi and 
Plasmodium falciparum (P. falciparum) .l0 P. falciparum is responsible for severe malaria and is 
associated with high mortality and morbidity. P falciparum is accountable for 99% of malaria 
related deaths in Africa. The global incidence of P.vivax cases is about 4% and are most of this 
are seen outside the African continent.''
Transmission of malaria to humans begins when a female anopheles mosquito injects the parasite 
in the form of sporozoites, as it takes a blood meal from a human. The sporozoites travel through 
the bloodstream to invade hepatocytes. Over a period of 2 weeks they replicate to produce 
thousands of merozoites. Only P. vivax & P. ovale remain dormant in the hepatocytes for 
prolonged periods, where they can cause a relapse of the disease months to years later. The 
merozoites are released in the bloodstream to then invade the erythrocytes to develop into 
trophozoites and schizonts. Gametocytes develop once released from the erythrocytes and these 
are the infective stage for the mosquito. The lifecycle is complete when a mosquito then takes a 
blood meal, infecting the anopheles mosquito.10,12
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1.3 PATHOGENESIS OF MALARIA
P. falciparum primarily invades erythrocytes. The pathophysiology and clinical manifestations of 
malaria are, to a large extent, related to this erythrocytic invasion. The removal of infected 
erythrocytes by splenic macrophages results in the activation of the innate immune system and 
resultant release of cytokines. The infected erythrocytes adhere to vessel walls and to uninfected 
erythrocytes, resulting in interference with the microcirculation. This disturbance of flow and 
tissue perfusion can lead to ischaemic tissue injury.10"13
The release of cytokines also leads to expression of adhesion molecules by endothelial cells; this 
mediates parasite sequestration. Nucleic acids released from destroyed parasites activate toll-like 
receptors inducing the expression of interleukin-12 that promotes production of interferon 
gamma. Interferon gamma has a number of functions, with the primary function being to control 
parasite replication in the liver. Its other functions include recruitment of leucocytes; promoting 
opsonisation of infected erythrocytes and cytokine production.12' 13
The consequences of these processes lead to persistent endothelial dysfunction promoting 
thrombosis; capillary leak with extravasation of fluid. Infected patients then present with two 
well-known manifestations of severe malaria, which are acute respiratory distress syndrome 
(ARDS) and cerebral malaria. Anaemia occurs due to haemolysis of infected and uninfected 
erythrocytes and cytokine-induced impairment of erythropoeisis. The release of oxygen free 
radicals and alteration in blood flow are responsible for the organ specific syndromes such as 
hypoxia, lactic acidosis, renal failure and cerebral malaria- features of severe malaria.1315
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1.4 SEVERE MALARIA IN THE INTENSIVE CARE UNIT (ICU)
1.4.1 Definition and Clinical Features of Severe Malaria
The WHO defines severe malaria as a complicated malaria infection, characterized by either 
organ failure or biochemical and haematological impairment.16 In the early stages, the severity of 
disease can be masked by non-specific symptoms. Malaria is a mimicker of many conditions. 
When the disease becomes severe; severe anaemia, respiratory distress, metabolic acidosis 
secondary to acute kidney injury, non-cardiogenic pulmonary oedema and cerebral malaria 
occurs.10' 14
1.4.2 Management of Severe Malaria in ICU
The clinical manifestations of severe malaria and response to optimal ICU management is 
dependent on the infectious plasmodium species; host factors which include age, comorbid 
illnesses, previous immunity and pregnancy status. These are also used as predictors of poor 
outcome.14
The WHO has identified several preventative measures such as disease control using treated 
mosquito nets, chemoprophylaxis given to travelers visiting malaria endemic areas, surveillance 
with notification of all malaria cases and lastly eradication of malaria. These prevent the 
development of acute malarial infections with the associated high mortality and morbidity. These 
strategies however, do not impact the outcomes of patients with severe malaria in ICU, once they 
have contracted the disease. Therefore, patients with severe malaria need to be managed in an 
ICU with close monitoring. Severe malaria is a medical emergency with a high mortality if left 
untreated.14
5
1.4.2.1 Medical Therapy 
Artesunate therapy
Artesunate is one of a number of anti-malarials derived from artemisinin, the active ingredient in 
a Chinese herbal remedy for fever known as Artemisia annua. Artesunate can be given 
intramuscularly or intravenously, reaching peak levels within the first hour of administration.4 
Artemisinin derivatives clear parasites faster and are observed to have a broader spectrum of 
activity than quinine. Importantly, they are effective in preventing the accumulation of young 
forms of the parasite in the microcirculation of vital organs and hence halt the progression to 
severe disease. Artesunate is the preferred drug of choice for treating severe malaria in the ICU.
It has consistently shown superior anti-malarial properties especially in parasite clearance, with a 
good side effect profile.2-4' 17
Artesunate is currently available through the parenteral artesunate access programme, developed 
by the Department of Clinical Pharmacology at the University of Cape Town, implemented in 
June 2009. The objective was to create access to parenteral artesunate by patients with severe 
malaria in South Africa (SA). Artesunate is not yet registered in SA with the Medicine Control 
Council (MCC) and is only available in terms of Section 21. In terms of this act, the MCC has 
authority with any transactions pertaining to artesunate and its use by persons and institutions. 
There are selected sentinel hospital sites based on their likelihood of treating most of the severe 
cases of malaria in South Africa. Chris Hani Baragwanath Hospital (CHBAH) in Gauteng is one 
of the hospitals administering artesunate to patients with severe malaria.18
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In the non-ICU setting, the mortality benefit of artesunate over quinine has been shown.2 The 
South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) was an open label, 
randomised trial, done on mostly adult patients with severe malaria. Patients were recruited and 
mostly managed in general medical wards. Few patients were in ICU. The trial was stopped early 
due to the substantial survival benefit in the artesunate group. Artesunate reduced mortality of 
severe malaria in Asian patients from 23.1% to 14.2%.17
The second biggest trial, artesunate versus quinine in the treatment of severe falciparum malaria 
in African children (AQUAMAT), was done in an African paediatric population. This was an 
open label, randomised trial conducted in nine African countries. Significant reduction in 
mortality in the artesunate group was found. These studies prompted the WHO to change its 
guidelines in advocating for the use of artesunate in patients with severe malaria.2
Artemisinin resistance is characterized by a delay in parasite clearance time. Artemisinin 
compounds derived from the plant Artemisia annua include artesunate, artemether and arteether. 
According to WHO definition, artemisinin resistance should be suspected in a population if more 
than ten percent of patients have not cleared the parasite in three days after the start of 
artemisinin based therapy.19 There have been recent reports in Southeast Asia, confirming 
artemisinin resistance in five countries. A study done by White L.J et al. emphasizes the need for 
molecular markers to identify artemisinin resistance and the importance of the initial parasite 
load followed by another one done on the third day. Of interest is the current research in the 
ketch 13 mutation, which is found on the mutant parasite.20 The cause of this resistance seems to 
be multifactorial, depending on drug factors, parasite factors as well host factors. It is
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additionally not clearly defined how much parasite clearance is needed by day three. 
Combination therapy using two antimalarial drugs with different mechanism of action at the 
same time, has the potential to delay the development of resistance.21
Quinine therapy
For many centuries, quinine derivatives were the mainstay of treatment for all forms of malaria. 
There has not been much documented resistance to quinine as yet but the use of this drug is 
limited, mainly due to its unfavorable side effect profile. Quinine was discovered in the early 17lh 
century and is it is a component of the bark of the Cinchona tree. Its antimalarial mechanism of 
action is unknown; however, it remains an important drug in the treatment of severe malaria. It 
has rapid schizonticidal action against intra-erythrocytic malaria parasites but no gametocidal 
effects on P. falciparum. It is well absorbed orally and parenterally. Quinine has a narrow 
therapeutic index and is associated with a number of devastating side effects which include 
vertigo, tinnitus, gastrointestinal disturbances and hypoglycemia. Hypoglycemia is a common 
side effect of quinine and occurs up to thirty-two percent of patients who receive this drug.21"22
Quinine is the oldest antimalarial to be discovered, and remains effective against falciparum 
malaria but sporadic cases of clinical failures were reported from South East Asia and South 
America.2’ The Plasmodium falciparum genome can encode multiple predicted polymorphisms 
in transport protein, predisposing it to resistance. These parasite transporters have an impact on 
different antimalarials and their responsiveness to the parasite. There are in vitro tests that 
suggest quinine resistance is associated with the following sodium transporter polymorphisms; 
plasmodium multidrug resistance protein -1 (PfMRPl), plasmodium multidrug resistance-
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1 (PfMDRl), plasmodium falciparum chloroquine resistance transporter {PfCRT). When these 
three genes are present P. Falciparum is less responsive to quinine. Interestingly PfCRT is the 
molecular marker and primary mediator of chloroquine resistance.24
Quinine is structurally related to chloroquine but malaria parasites resistant to chloroquine are 
still sensitive to quinine. Resistance to quinine is less frequent in Africa, and in the last two 
decades the drug has been used in combination with doxycycline to enhance its effectiveness.23
1.4.2.2 Complications of severe malaria and supportive treatment in ICU 
Acute respiratory distress syndrome
This is a complication that develops in about thirty percent of adult patients and more commonly 
in pregnant females. The development of ARDS is a poor prognostic sign. The indications for 
mechanical ventilation in patients with severe malaria is not different from any other medical 
conditions. This may include poor respiratory effort, ARDS, severe metabolic acidosis and 
aspiration pneumonia.26 In the absence of mechanical ventilation mortality outcome exceeds 
eighty percent and with ventilation it can still exceed fifty percent, especially among patients 
infected with Falciparum.13 The mechanism underlying ARDS is poorly understood but 
endothelial dysfunction and altered capillary permeability have been suggested as contributory. 
Treatment is the same as for any other cause of ARDS, which includes lung protective 
ventilatory strategies. Mechanical ventilation with lower tidal volumes, moderate to high positive 
end expiratory pressure are used to maintain oxygenation. Fluid balance is significant to monitor 
as fluid overload can exacerbate this condition.27 28
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Co-infection and use of antibiotics
Bacterial co-infection should be suspected in patients with signs of sepsis, significant 
neutrophilia, rising C-reactive protein and a deteriorating clinical condition. Concurrent gram­
negative non-typhoid salmonellae has been shown to be common in endemic areas especially 
affecting children. Other common affecting organisms include Pneumococci, E.coli and other 
gram-negative organisms. There should be a low threshold to the use of broad spectrum 
antibiotics.26'27
Renal failure, haemodialysis and fluid therapy
This is commonly seen as oliguric (<400ml/day) kidney injury in about sixty to seventy percent 
of cases.13 The incidence is higher in non-endemic regions, while in endemic regions it varies 
from one to five percent. Histopathological findings are similar to those of acute tubular necrosis, 
although hypovolemia and haemolysis maybe contributory. The urine assessment is usually 
unremarkable, unless patients have “blackwater fever”. This refers to a condition where a patient 
passes dark red or brown urine, secondary to haemolysis that then results in haemoglobinuria.2y 
Blackwater fever can occur in patients treated with quinine, and may also be associated with 
glucose-6-phosphate dehydrogenase deficiency. It is usually transient, reflecting massive 
haemolysis and does not indicate severe renal impairment.26"27
Early renal replacement therapy, either haemofiltration or haemodialysis improves outcomes.
The return of creatinine to normal, is a mean average of seventeen days.lj Haemofiltration has 
proved to be superior when compared to peritoneal dialysis, especially in the 1CU setting.26 
Trials of dopamine and epinephrine to improve renal outcomes have not been shown to improve
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renal perfusion.24 Quinine needs adjustment with renal impairment unless patient is on renal 
replacement therapy but there’s no need for adjustment with artesunate.29 The prognosis of acute 
kidney injury secondary to severe malaria is good.27
Fluid balance is an important issue in patients admitted with severe malaria to ICU. Aggressive 
fluid therapy is best avoided in these patients because of the risk of ARDS and cerebral oedema 
due to capillary leakage. A neutral fluid balance should be maintained for adequate systemic 
perfusion. A balance is critical to avoid precipitating acute kidney injury with a negative fluid 
balance. In case of hypotension, early use of inotropic support is indicated to prevent fluid 
overload.27
Neurological complications
Cerebral malaria is defined as a depressed level of consciousness, ranging from agitation, 
confusion, seizures or GCS below eleven that can’t be explained by any other aetiology.16 
Cerebral malaria is usually complicated by cerebral oedema. It is associated with poor outcomes, 
despite the use of anticonvulsant therapy in patients with seizures. There are no adjunctive 
therapies that are currently recommended for cerebral malaria. There is no indication for the use 
of dexamethasone in cerebral malaria. Using steroids might prolong the period of coma as well 
as predispose patients to other side effects of steroids.26"27
Hypoglycaemia
This is defined as blood glucose less than 2.2mmol/l, this is particularly common in the 
paediatric population. This can be caused by parasite glucose consumption or impaired hepatic
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gluconeogenesis in a patient with severe malaria. Hypoglycaemia maybe worsened by the use of 
intravenous quinine and can be avoided by regular monitoring and early enteral feeding.26
1.5 THE IMPACT OF THE MALARIA EPIDEMIC ON THE AFRICAN CONTINENT
Sub-Saharan Africa carries a high global burden of malaria cases. According to the WHO, about 
thirteen countries, mainly in Sub-Saharan Africa, account for seventy-six percent of malaria 
cases and seventy-five percent of malaria related deaths globally. Prevention and control 
strategies have led to twenty-nine percent reduction in malaria mortality rates since 2009.7 
The disease burden in African regions is further worsened by lack of resources, poor vector 
control measures and lack of access to treatment.30 South Africa, however, has a relatively well- 
organized malaria control program and a relatively well-developed health infrastructure 
compared to our African counterparts.31
1.6 MALARIA INFECTION IN THE HIV INFECTED POPULATION
In Sub-Saharan Africa, 24.7 million people are living with HIV.32 South Africa has the largest 
epidemic of HIV, and accounts for 17 percent of all AIDS related deaths in Sub-Saharan Africa. 
According to statistics SA, 16.8 percent of the population of adults aged between 15-49 years are 
estimated to be living with HIV.33
A link between HIV infection and severity of malaria has been demonstrated. A South African 
prospective study done by Cohen et at, showed that HIV infected non-immune adults are at an 
increased risk of severe malaria. This is associated with low CD4 counts.34 This was further 
shown in studies in Malawi and Zambia which showed high risk of malaria re-infection in HIV
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infected patients with CD4 counts less than 200. A prospective study done in Mozambique, 
which compared malaria infection in HIV versus non-HIV infected patients, revealed high 
morbidity and mortality in the HIV infected group. The mortality was twenty six percent in the 
HIV infected group versus nine percent in the non-HIV infected group. It must also be taken into 
consideration that this study was conducted in a malaria endemic region.35-36
1.7 PROBLEM STATEMENT
There is paucity of South African data regarding the outcomes of patients with severe malaria 
treated with quinine compared to those treated with artesunate in the intensive care unit. Bruwer 
et al at Tygerberg hospital in the Western Cape, a non-endemic area in South Africa, did a 
descriptive study reviewing the demographic, clinical and laboratory prognostic indicators of 
patients with severe malaria, in a tertiary intensive care unit.6 However the sample size consisted 
of only sixteen adult patients and there was no comparison of the treatment modalities.
The SEAQUAMAT trial was done in South-East Asia, in a different setting to our study.17 
Soweto is a township, urban area with a high prevalence of HIV, a non-endemic area but high 
numbers of imported malaria from our neighbouring countries. This proposed retrospective study 
was conducted in an intensive care unit where patients received close monitoring, allowing for 
the observance of intensive care unit therapy on malaria. This will hopefully add to the growing 
body of evidence about the efficacy of artesunate in reducing severe malaria mortality in an 
intensive care unit setting.
13
1.8 AIMS AND STUDY OBJECTIVES
1.8.1 Aim of the study
The aim of this study was to compare the outcomes between patients treated with artesunate 
versus quinine. The study was done from 2008 to 2012 at Chris Hani Baragwanath Academic 
Hospital intensive care unit (CHBAH 1CU).
1.8.2 Study Objectives
• To determine whether artesunate was effective in treating severe malaria when compared 
to quinine in an ICU setting.
• To assess and compare the APACHE 11 scores on admission of patients treated with 
quinine versus those treated with artesunate and the impact it had on the outcome.
• To compare the biochemical and haematological laboratory data of patients treated with 
quinine versus those treated with artesunate in ICU.
• To compare invasive and non-invasive interventions performed in ICU for patients with 
severe malaria treated with quinine versus those treated with artesunate therapy.
1.9 PRIMARY AND SECONDARY OUTCOMES
• Primary outcome measures were length of stay in ICU and in-ICU death or discharge 
from ICU.
• Secondary outcome measures were neurological status, as determined by level of 
consciousness (GCS) on admission and discharge as well as the number of 
hypoglycaemia episodes during ICU stay.
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1.10 DEFINITION OF VARIABLES
• Travel history- a history of traveling outside of South Africa in the last 3 months.
• Comorbidities- concurrently present morbidities including HIV co-infection.
• SOFA score- Sequential organ failure assessment score, to determine the extent of a 
patient organ function or rate failure during ICU stay.
• APACHE II score- a scoring system designed to measure the severity of disease in 
patients admitted to ICU, applied within 24 hours of admission to ICU.
• Neurological status as defined by the admission Glasgow coma score (GCS). Participants 
were divided into three groups, participants with GCS ofO-11, 12-14 and GCS 15.
• Lactate level- participants were grouped and recorded into two groups; those with a 
lactate level more than 5 mmol/l and those with a lactate less than 5 mmol/1
• Parasite level of more than two percent was considered as significant in our study.
• Creatinine level on admission in mcmol/1
• Metabolic acidosis- defined as plasma bicarbonate level less than 15mmol/l.
• The need for inotropic support- was documented on the data collection sheet as YES or 
NO and cumulative doses were recorded.
• The need for mechanical ventilation - was documented on the data collection sheet as 
YES or NO.
• The need for renal replacement therapy- was documented on the data collection sheet as 
YES or NO.
• Hypoglycemia was defined as HGT level less than 2.2 mmol/l.
• Total length of stay in ICU- participants were grouped into three groups: less than 5 days 
stay in ICU, more than 5 days stay in ICU and the group within 5days.
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• Neurological status was assessed using GCS on discharge, psychiatric or other focal 
neurological signs were noted.
• Arrhythmias during 1CU stay -  abnormalities of rhythm were documented.
• 1CU outcome- was defined as in- ICU death or discharge from ICU.
• Non-invasive intervention - a diagnostic or therapeutic procedure that does not require 
incision through skin or insertion of an instrument to a body orifice.
• Invasive intervention - a diagnostic or therapeutic procedure that involves skin incision or 
penetration of a body orifice by using an instrument.
1.11 METHODS
1.11.1 Study Design
This was a retrospective cohort study of patients with malaria treated in ICU with artesunate and 
those treated with quinine. All admissions with severe malaria from the 1st of January 2008 to 
3 1st of December 2012 were included.
1.11.2 Study setting
This study was conducted at CHBAH ICU. CHBAH is a three thousand bed academic hospital, 
affiliated to the University of the Witwatersrand in Johannesburg, South Africa. It serves mainly 
the community of Soweto but is also a referral hospital for most surrounding towns and other 
provinces. The internal medicine department is the largest and busiest in the hospital, comprising 
of about seven hundred and seventy-six beds.
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1.11.3 Study Sample
The study sample included all patients who were admitted at CHBAH ICU with the diagnosis of 
malaria from the 1st January 2008 to 3 1st December 2012. All patients admitted to CHBAH ICU, 
fulfilling the WHO criteria for severe malaria, were included in the study. This included adult 
over or equal to the age of 18 years. The patients were treated with either quinine or artesunate 
therapy in ICU.
1.11.4 Data Collection
Patients admitted to Chris Hani Baragwanath hospital are logged into the ICU admitting book 
system with clear admission diagnosis and relevant demographic data. Details of all the patients 
with a diagnosis of severe malaria were obtained, these were correlated with their ICU files that 
are kept in the ICU records room. The artesunate book which has records for all patients who 
were admitted with severe malaria and received artesunate was used as a cross reference. The 
following flow diagram would further illustrate the sampling process.
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Total number of patients with 
severe malaria:
N= 102
Total excluded: 
Age < 18 
N=4
Total above Age 18: 
N=98
Total excluded due to 
inadequate records: 
N=6
Total number included in 
the study:
N=92
Figure 1: Study Participants
1.11.5 Statistical Analysis
The data collection sheet (Appendix B) was used for data collection. Data was analysed using 
STATA version 13, with the help of a statistician. Categorical variables were expressed using 
frequency distributions. Continuous data were expressed using mean, range and percentages. The 
statistical test that was used to compare the outcome of the two therapies in our study was the 
two samples student t-test. A p value of <0.05 was considered to be statistically significant.
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1.12 LIMITATIONS
The following limitations of the study have been identified. The sample was small and may not 
be representative of the national group of critically ill patients with malaria. Therefore, results 
might not be generalized to most patients with severe malaria in ICU.
Bias may have occurred due to the retrospective nature of the study design. We had to rely on 
information that was available in the ICU charts. The other challenge was that the files are not 
kept in an electronic database, making it difficult to account for missing data. The possibility of 
inclusion bias exists, since ICU admission is often a clinician and management based criteria. 
The admission threshold may be different depending on the clinician requesting the admission 
and the intensivist assessing the request for admission. Resource limitation and ICU bed 
availability in our setting means some cases of severe malaria who may have required intensive 
care unit admission were treated in other wards such as the medical High Care Unit in our 
hospital or the obstetrics High Care Unit.
1.13 ETHICS
This was a retrospective review of data. All patients given artesunate in our unit had signed 
informed consent as part of MCC approval or consent had been obtained from a legal proxy. 
Ethics approval was obtained from the Human Research Ethics Committee of the University of 
the Witwatersrand as well as the University's Postgraduate Committee before commencement of 
the study (Ethics clearance certificate number: M50120). Permission was also obtained from the 
hospital management of CHBAH as well as the University of Cape Town's clinical 
pharmacology department to conduct this study.
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Confidentiality of subject data was maintained at all times and subject anonymity was 
guaranteed. All documentation relating to the subject was kept in a secure location. The names 
and identification numbers of the patients were assigned a number on a restricted access excel 
document. Confidentiality was guaranteed in any resulting publication.
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ABSTRACT
Background
Malaria is a preventable and treatable disease that is a major burden in the African sub-region, 
accounting for 75% of malaria related deaths globally. Prior to December 2009, quinine has been 
the therapeutic option of choice for the management of Malaria in our unit. In the non-intensive 
care unit setting a mortality benefit of artesunate over quinine has been shown by two major 
trials and thus artesunate is currently therapy of choice for severe malaria. There is paucity of 
South African data regarding the outcomes of severe malaria patients treated with quinine 
compared to those treated with artesunate in the intensive care unit (ICU).
Objectives
The aim of this study was to compare the outcomes of patients treated with artesunate versus 
those treated with quinine, over a four-year period in our ICU. The primary outcome variables 
were length of stay and mortality, secondary outcomes where hypoglycaemia episodes and 
neurological outcome as measured by GCS on admission and on discharge.
Methods
This was a retrospective cohort study of patients with severe malaria treated at Chris Hani 
Baragwanath Academic Hospital with artesunate or quinine. The study was done in an ICU 
setting. This included a review of patients treated in the unit from 1st January of 2008 to 3 1st 
December 2012. A p value of<0.05 was chosen as a measure of statistical significance.
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Results
The sample consisted of 92 patients. Forty three percent (n=40) received quinine and 57% (n = 
52) received artesunate. There was no statistically significant difference between the two drugs 
in the treatment of severe malaria in our ICU with regards to length of stay (p=0.738), mortality 
(p=0.246), hypoglycaemia (p= 0.246) and neurological outcome as measured by GCS on 
admission and discharge (p= 0.357).
Conclusion
In our intensive care population the difference in outcomes between artesunate and quinine were 
not statistically significant. Artesunate did not confer an obvious benefit over quinine. 
Considering the differences in cost, logistical differences associated with the use of the two drugs 
as well as the emergence of artesunate resistance, we suggest that outcomes of artesunate versus 
quinine be investigated in other non-endemic regions.
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INTRODUCTION
Malaria is a preventable and treatable disease that is a major burden worldwide and more 
especially in the African sub-region. In 2012, about 207 million cases were reported worldwide. 
The majority of these were in the Sub-Saharan region.1 The disease is more prevalent in the 
tropics, and despite preventative measures it remains a major reason for hospital admission in 
Sub-Saharan countries.2 South Africa (SA) malaria transmission is seasonal and regional 
between October and May.3 4
Sub-Saharan Africa carries a high burden of malaria related deaths, accounting for about 75% of 
deaths globally.5 Unfortunately, most of the mortalities occurs in the under-five age group, an age 
group more susceptible to severe malaria infection.1 According to WHO the malaria incidence 
has decreased by 29% globally between the period of 2010 and 2015.5 The global technical 
strategy for malaria 2016-2030, aims to decrease malaria incidence and mortality rates by at least 
90% in 2030.6
In the non-lCU setting, studies have shown mortality benefit of artesunate over quinine.2 7 The 
South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) was an open label, 
randomised trial, involving 1461 patients with severe malaria. The mortality in the artesunate 
group was 15% compared to 22% in the quinine group (p=0.000). The trial was stopped early 
due to the substantial survival benefit in the artesunate group.7
The second biggest trial, artesunate versus quinine in the treatment of severe falciparum malaria 
in African children (AQUAMAT), was done in an African paediatric population. This was an
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open label, randomised trial conducted in nine African countries, all malaria endemic regions. 
The primary outcome was in hospital mortality, 8.5% in the artesunate group compared to 10.9% 
in the quinine group, (p=0.002). Overall reduction in mortality in the AQUAMAT study was 
22.5% (p=0.002). The results of these two trials prompted the WHO to change its guidelines and 
to advocate for the use of artesunate in patients with severe malaria.2
Challenges relating to the availability of artesunate was an initial barrier to its use in our hospital. 
Artesunate is not currently registered in South Africa. It is only available on a named patient 
basis via the parenteral artesunate programme, which was approved in 2009 for patients 12 years 
and older with severe malaria.8
Additionally, there is paucity of South African data regarding the outcomes of patients with 
severe malaria treated with quinine compared to those treated with artesunate in the ICU.
South Africa (SA) is noted as a low transmission area, however malaria is endemic in three 
provinces of South Africa, Mpumalanga, Kwazulu Natal and Limpopo. Transmission is usually 
seasonal, between October and May, with the spread of malaria being increased by travelers and 
migrant labour from neighbouring Sub-Saharan states.3"4 Gauteng, the region in which our study 
is set, is a non-endemic area. Furthermore, the two large trials AQUAMAT/SEAQUAMAT did 
not include patients managed in the ICU where close monitoring and one to one nursing is the 
standard.2,7 Close monitoring in an ICU setting allows for early detection and management of 
potential complications of the disease or therapy. Currently two studies have been done in South 
Africa, both looking only at prognostic indicators in a non-endemic area.9"10
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The aim of the study was to compare outcomes between patients treated with artesunate versus 
those treated with quinine at CHBAH ICU. The primary outcome was the length of stay in ICU 
and mortality in patients with severe malaria who were treated with artesunate versus quinine. 
Secondary outcomes were assessing neurological status (assessing level of consciousness on 
admission and discharge) and number of hypoglycemic episodes (defined as a glucose level less 
than 2.2mmol/L) on the two therapies.
METHODS
The study was conducted at Chris Hani Baragwanath Academic Hospital ICU (CHBAH ICU). 
CHBAH ICU is a tertiary level ICU affiliated to the University of the Witwatersrand, in 
Johannesburg, South Africa. The hospital is located in the South-Western townships of 
Johannesburg (Soweto). Surgical and medical patients are both admitted into the unit and 
referrals come mainly from the community of Soweto as well as from peripheral hospitals in the 
surrounding towns and provinces. Soweto is classified as a low malaria transmission area. The 
malaria cases admitted into our unit are mostly travelers, who travel back from malaria endemic 
regions in the neighbouring regions.
Ethics approval was obtained from the Human Research Ethics Committee (Medical) of the 
University of the Witwatersrand prior to commencement of the study (Ethics clearance certificate 
number M l50120, approved 20/02/2015).
30
Study population and data collection
This was a retrospective cohort study of patients with severe malaria treated in ICU with 
artesunate and quinine. The study sample included all patients who were admitted to CHBAH 
ICU with the diagnosis of malaria whose files could be found in our records from the period of 
01 January 2008 to 31 December 2012. These included adults aged 18 years or above, who met 
the WHO guidelines for severe malaria. There were no exclusion criteria. Details of all patients 
with a diagnosis of severe malaria from the ICU were obtained from ICU records. The following 
flow diagram further illustrates the sampling process.
Total number of patients with 
severe m alaria 
N= 102
Total excluded: 
A g e  < 18 
N=4
Total above A g e  18: 
N=98
Total excluded due to 
inadequate records: 
N=6
Total number included in 
the study:
N=92
Figure 1: Study Participants
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Statistical Analysis
Data analysis was conducted using STATA version 13. Categorical variables were expressed 
using frequency distribution, chi square test and t-test. Continuous data was expressed using 
descriptive statistics such as mean, range and percentages. The two samples t-test was used to 
compare the outcome of the two therapies. Probability levels of less than 0.05 were accepted as 
statistically significant.
RESULTS
Demographics
The sample consisted of 92 patients. There were 64 males and 28 females. Of the 92 patients, 
43% (n = 40) received quinine while the other 57% (n = 52) received artesunate. The mean age 
of patients in the quinine group was 36 compared to 40 in the artesunate group (p =0.071). Most 
of the patients (98.6%) had a positive travel history to a malaria endemic region. Regarding HIV, 
53 patients were tested, and of these 71.7% tested HIV positive while 28.3% tested negative 
(p=0.520). The average CD4 count of HIV positive patients treated with quinine (cells/mm3) was 
200, and was 217 for those treated with artesunate (p= 0.875). The sample distribution is shown 
in the following figure:
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■ Quinine
■ Artesunate
Figure 2: Antimalarial drug administered in ICU 
Primary outcome
There was no statistically significant difference between the artesunate and quinine groups with 
regards to length of stay in ICU (p=0.738) and mortality (p = 0.246). With regards to patients 
admitted for less than five days, 45% (n=40) received quinine and 46.2% (n=52) received 
artesunate. With regards to patients admitted longer than five days, 42.5% (n=17) received 
quinine while 46% (n=24) received artesunate.
There was no significant association between the drug received and mortality (p = 0.246). A total 
of 10 patients died, those that received quinine, 84.6% (n=33) survived till discharge and 15.4% 
(n =6) died in ICU. With regards to the artesunate group, 89% (n=46) survived till discharge 
while 11% (n= 4) died in ICU.
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Secondary outcomes
The mean Glasgow coma scale on admission in patients treated with quinine was 11.6 versus
12.4 in the artesunate group (p= 0.302). The mean GCS on discharge was 14.9 for patients 
administered quinine versus 14.1 for patients who received artesunate (p= 0.081).
Nine patients died in ICU with an overall mortality rate in ICU of 11%. The most common 
neurological complication was seizures accounting for 39.3% in the total sample (p= 0.357). The 
number of hypoglycaemia events were two (5.9%) in the quinine group compared to none in the 
artesunate group (0 %). The average blood glucose level (mmol/1) was 5.69 for patients treated 
with quinine and 6.41 for patients treated with artesunate (p= 0.596).
Biochemical and hematological tests
The mean parasite count in percentages for patients who received quinine was 0.12 and 0.14 for 
patients who received artesunate (p= 0.416). There was no difference in the mean bicarbonate 
level (mmol/l) on admission between patients who received quinine (17.2 mmol/l), and those 
who received artesunate (18.4 mmol/l) (p=0.241). The mean lactate level (mmol/l) for patients 
who received quinine was 5.23 and 4.37 for those who received artesunate (p= 0.291). 
Hemoglobin levels (g/dl) were similar with mean levels of 8.47 and 8.96 for those who received 
quinine and those who received artesunate respectively (p= 0.425). Creatinine (mcmol/l) on 
admission for patients using quinine were on average 300 and patients on artesunate therapy 390 
(p= 0.187). The APACHE 11 score on admission was similar in the two groups, patients on 
quinine had an average of 20.85, while those on artesunate had an average of 19.62 (p= 0.380).
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Invasive management
The duration of inotropic support on patients treated with quinine was on average 4.6 days 
compared to 3.5 days for those treated with artesunate (p= 0.423). There was no difference 
regarding the duration of renal support, those on quinine needed renal replacement therapy for an 
average of 6.0 days while those on artesunate had on average 6.6 days (p= 0.730). The average 
number of days needed for mechanical ventilation for patients treated with quinine was 5.5 days 
compared to 6.0 days for those patients treated with artesunate (p= 0.812).
Table 1: History and Clinical Data of patients on antimalarials in ICU
Variable C ategories Q uin ine A rtesun ate Total P -va lu e
n 3 9 52 91
G ender F em ale 3 3 .3 % 2 8 .8% 30.8% 0 .6 4 6
M ale 6 6 .7% 71.2% 6 9 .2 %
N 29 41 70
T ravel Y es 100.0% 9 7 .6% 9 8 .6% 1.000
N o 0.0% 2.4% 1.4%
N 17 3 6 53
HIV P o sit iv e 6 4 .7% 75.0% 71.7% 0 .5 2 0
N e g a tiv e 3 5 .3% 2 5 .0% 2 8 .3%
N 12 10 22
Pregnant 4 1 .7% 10.0% 2 7 .3%
O b ese 0 .0% 2 0 .0% 9.1%
H ypertension 8 .3 0 10.0% 9.1%
C om orb id ities
A sth m a 0.0% 2 0 .0% 9.1%
0.201
P rev iou s T B 16.7% 0.0% 9.1%
P rev iou s m alaria 8.3% 10.0% 9.1%
D ia b etes m ellitu s 8.3% 0.0% 4.5%
Isch aem ic  heart 
d isea se
8.3% 0.0% 4.5%
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C hron ic k id ney  
d isea se
0 .0% 10.0% 4.5%
E p ilep sy 0.0% 10.0% 4.5%
P reviou s m alaria &  
E p ilep sy
0 .0% 10.0% 4.5%
H yp erten sion  &  
B en ig n  prostatic  
hypertrophy
8.3% 0.0% 4.5%
N 4 0 52 92
I notropes Y es 6 7 .5% 5 7 .7% 62.0% 0 .3 3 7
N o 32.5% 4 2 .3 % 38.0%
N 4 0 52 92
R enal support Y es 52 .5% 5 9 .6% 56.5% 0 .4 9 5
N o 4 7 .5 % 4 0 .4% 43.5%
N 4 0 52 92
M echan ica l
ven tila tion
Y es 50 .0% 2 6 .9% 37.0% 0 .0 2 3
N o 50.0% 73.1% 63.0%
N 17 11 28
Seizu res 4 1 .2% 36.4% 39.3%
D ro w sy 17.6% 9.1% 14.3%
Pulm onary ed em a 0.0% 18.2% 7.1%
V ision  lo ss 5.9% 0.0% 3.6%
S p eech  d efect 0 .0% 9.1% 3.6%
N e u ro lo g ica l
c o m p lica tio n s
P sy ch o sis 5.9% 0.0% 3.6%
0 .3 5 7
A R D S 11.8% 0.0% 7.1%
C on fu sion 0 .0% 9.1% 3.6%
S p len ic  in farcts 5.9% 0.0% 3.6%
P rolonged  Q T / cardiac  
arrest
5.9% 9.1% 7.1%
U pper G IT  b leed in g 0 .0% 9.1% 3.6%
H y p o g ly ca em ic
ep iso d e s
5.9% 0.0% 3.6%
Length o f  stay N 4 0 52 92 0 .7 3 8
36
<5 days 4 5 .0 % 4 6 .2% 4 5 .7%
E xactly  5 days 12.5% 7.7% 9.8%
>  5 days 4 2 .5% 4 6 .2 % 4 4 .6%
N 3 9 52 91
O u tcom e D ischarge 84 .6% 9 2 .3% 89.0% 0 .2 4 6
D eath 15.4% 7.7% 11.0%
DISCUSSION
Malaria is a major cause of death in Sub-Saharan Africa. South Africa, specifically the Gauteng 
province, is considered a non-endemic region. However, there is an increasing number of cases 
of severe malaria associated partly to travellers from endemic areas entering South Africa.4 In 
addition, South Africa has the highest HIV infection rate of any country in Africa making its 
citizens more susceptible to developing severe malaria as a result of immunosuppression.3
The average cost of parenteral artesunate is currently higher compared to quinine but however 
artesunate is cost effective, considering the reduction in mortality and shorter duration of 
treatment." Advantages of artesunate are rapid antiparasitic activity and a shorter half-life. The 
duration of treatment is seldom required beyond three days, ease of administration and rapid 
clinical benefit. Parenteral artesunate is easier to administer compared to quinine. It requires 
once daily intravenous administration, compared to quinine that requires a loading dose and 
thereafter three times per day intravenous dosing. 12
Treatment with artesunate is well tolerated with minimal side effects compared to quinine. The 
main adverse effects that have been reported since the initiation of the artesunate programme 
have been renal failure and haemolysis." Quinine is associated with a number of side effects,
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hypoglycaemia being one of the more common ones.8 Parenteral quinine requires dose 
adjustment in patients with renal impairment, a condition frequently encountered in patients with 
severe malaria."
The main disadvantage is that artesunate is not currently registered in SA. Access is only 
available on a named patient basis via the parenteral artesunate programme, which was approved 
in 2009 for patients 12 years and older with severe malaria.8
The World Health Organization (WHO) defines severe malaria as a complicated malaria 
infection, characterized by either organ failure or biochemical and haematological impairment. 
Severe malaria often requires admission to an ICU in order to manage complications of multi­
organ failure.13
Several large studies have shown that artesunate is superior to quinine in the treatment of severe 
malaria.2,7 None of the studies comparing the two drugs were done in South Africa in an ICU 
setting. As mentioned before South Africa is a non-endemic region and despite the low 
transmission rate, the case fatality rate has remained unchanged in over a decade, at 0.76%,
0.26% above the WHO target of 0.5%. This could be due to a number of factors, such as delay in 
seeking treatment, delay in the diagnosis of malaria, co-morbid illnesses, ineffective treatment of 
uncomplicated malaria, adverse effects of therapy such as hypoglycaemia and fewer hospitals 
with ICU’s. The ICU environment allows for detailed management, close observation as well as 
early detection of complications."
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Two studies have been done in an 1CU setting in South Africa. Blumberg et al, at CHBAH ICU 
assessed predictors of mortality in severe malaria over a 2-year period (1993 to 1994). These 
were clinical and laboratory features that are used to define severe malaria according to the 
WHO. The study included 28 patients with severe malaria treated with quinine. The setting and 
study population was similar to our study. Pregnancy was found to be a major risk factor for poor 
outcome in this study, other parameters such as high APACHE II scores, high lactate and 
negative base excess within the first 24 hours of admission were also associated with poor 
outcomes.10
The second study was a descriptive study done by Bruwer et al, at Tygerberg hospital in the 
Western Cape, a low malaria transmission and non-endemic area in South Africa. They reviewed 
laboratory and clinical aspects of sixteen ICU patients with severe malaria. The mortality rate 
was 43.8% (n=7), and of interest, majority of the patients (93.8%) received quinine therapy.9
The sample size of these two studies was small and there was no outcome comparison between 
patients treated with quinine versus those treated with artesunate. In our study, we sought to 
investigate whether there would be an outcome different between patients treated with quinine 
versus artesunate in an ICU setting.
We found that there was no statistically significant difference between outcomes of patients with 
severe malaria in our ICU treated with artesunate and quinine in our study. Our findings are in 
contrast with results of two major trials SEQUAMAT and AQUAMAT which were however 
done in a different setting to ours. There were few factors which were different in our study;
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Apart from the differences in study designs most of the patients in our study were HIV positive 
(57.6%), our study was set in a non-endemic environment and ail our patients were treated in an 
ICU. This allowed for organ specific support interventions when necessary as opposed to the 
setting of the two major trials, wherein patients where mostly treated in general wards. There was 
no difference in the length of stay when using the different treatment modalities. This is 
consistent with results of the AQUAMAT trial, where the lime to discharge was 3 days in both 
the artesunate and the quinine group (p= 0.059).2,7
The mortality benefit seen with artesunate was greater in South East Asia compared to the 
African population. This may be because of less resistance to P.falciparum malaria in Africa to 
quinine.2,7 In our study there was no statistically significant difference in mortality between 
artesunate and quinine (p= 0.246). Mortality in the quinine group in our study (15.4%) was much 
lower compared to a study done prior by Blumberg et al in our ICU (28, 5%). Reasons for this 
could be a difference in co-morbidities such as HIV co-infection in the two groups.
Consistent with our findings is a study done in India comparing the efficacy of quinine and 
artesunate in severe P. falciparum malaria. This was a prospective randomised trial, open label in 
a tertiary center and included 35 patients who met WHO criteria for severe malaria. Eighteen 
received quinine and 17 received artesunate. The end points were parasite clearance time, fever 
clearance time, coma resolution time, adverse effects of the drugs and death. All patients were 
admitted to general wards, except four patients with acute respiratory distress syndrome admitted 
to ICU. One patient died in each arm. Patients treated with artesunate had shorter times to fever
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resolution and parasite clearance, while coma resolution was quicker in the quinine group. As 
with our study there was no mortality benefit of artesunate versus quinine in this study.14
We did not find any significant differences between neurological outcomes with the use of 
artesunate versus quinine. This is consistent with findings from the AQUAMAT trial where 
neurological sequelae were found to not be significantly different between artesunate and 
quinine. This finding has also been supported by other investigators. The development of 
convulsions, coma and the deterioration in the Glasgow coma scale score seems to be slightly 
higher in the quinine group.2 15 Further investigations to further evaluate this are warranted.
Hypoglycaemia is an important and treatable cause of death in severe malaria and is of 
multifactorial origin. This can occur on presentation and also during the course of treatment, 
mechanisms include impaired liver function in severe malaria leading to impaired 
gluconeogenesis and glycolysis and drug induced hyperinsulinaemia. In a recent Cochrane 
systematic review comparing artesunate versus quinine for treating severe malaria treatment with 
artesunate resulted in a significant reduction in mortality, parasite clearance and hypoglycaemia 
in patients with severe malaria in Asia. Artesunate appears to be associated with fewer 
hypoglycaemic episodes than quinine. The number of hypoglycaemia events documented on 
admission in our study were 5.9% in the quinine group compared to none in the artesunate group 
(p =0.357). The proposed mechanism is inappropriate insulin release from the pancreatic beta 
cell. Hypoglycaemia has however been observed in severe malaria without treatment with 
quinine.I'>' l/
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The emergence of resistance to artesunate in South East Asia has been reported in a number of 
studies and is characterized by decreased parasite clearance times. The common mutation 
associated with artemisinin resistance to falciparum malaria in Asia is the PfKelchl3 mutation.18' 
21 There seem to be a few mutations emerging from Africa as recently demonstrated in a case 
report of a patient who contracted falciparum malaria in Equatorial Guinea and failed treatment 
with artesunate.22"2’ Resistance was not a focus of our study but this case report highlights the 
importance of continued access to therapeutic options to artesunate.
More than half of patients included in our study were HIV positive. HIV associated 
immunosuppression has been postulated to increase the risk of contracting malaria and reducing 
the efficacy of anti-malarial therapy. Interestingly HIV and malaria infection follow the same 
geographical distribution. The full extent of the pharmacokinetic interactions between anti- 
malarial and anti-retroviral drugs used in the management of HIV is scarce due to limited 
published data. Difficulty in distinguishing adverse reactions from antimalarial therapy versus 
those of antiretroviral therapy or from severe malaria infection itself may pose a diagnostic 
challenge. The increased incidence of severe malaria in HIV infected patients is likely to 
augment the overall burden of disease, increasing morbidity and mortality in Sub-Saharan 
African population.24'23
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The current standard of care for the treatment of malaria is similar in HIV infected and non-HIV
infected individuals. Data shows use of antiretroviral therapy might reduce the morbidity of 
severe malaria in HIV infected individuals.26 Therefore early diagnosis and initiation of 
antiretroviral in our population can assist in reducing the morbidity and mortality associated with 
severe malaria. Further research is needed to clarify this in the future as well as the clinical 
implications of the use of antiretrovirals together with antimalarials.
Limitations encountered in our study was a small sample size that may not be representative of 
the national group of critically ill patients with malaria. Bias may have occurred due to the 
retrospective nature of the study design. The possibility of inclusion bias exists, since ICU 
admission is often a clinician and management based criteria. Resource limitation and ICU bed 
availability in our setting means some cases of severe malaria who may have required intensive 
care unit admission were treated in other units such as medical wards.
CONCLUSION
In our intensive care population the difference in outcomes between artesunate and quinine were 
not significant. Though our population had a high incidence of HIV co-infection, artesunate did 
not confer an obvious benefit over quinine. Artesunate is more expensive, not as easily accessible 
and furthermore, resistance to artemisinin combined therapy including artesunate is emerging. 
Quinine should thus continue to be considered a therapeutic option. We suggest that outcomes of 
artesunate versus quinine be investigated in other settings such as ICUs and non-endemic and 
population groups such as those with HIV co-infection.
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Table 1: History and Clinical Data of patients on antimalarials in ICU
V ariable C ategories Q u in in e A rtesunate Total P -va lu e
G ender
n 3 9 52 91
0 .6 4 6F em ale 33 .3% 2 8 .8% 30.8%
M ale 6 6 .7% 71.2% 6 9 .2%
T ravel
n 2 9 41 70
1 .000Y es 100.0% 9 7 .6% 9 8 .6%
N o 0.0% 2.4% 1.4%
H IV
n 17 3 6 53
0 .5 2 0P ositive 6 4 .7% 75.0% 71.7%
N e g a tiv e 3 5 .3% 2 5 .0% 2 8 .3%
C om orb id ities
n 12 10 22
0 .201
Pregnant 4 1 .7% 10.0% 27.3%
O b ese 0 .0% 2 0 .0% 9.1%
H ypertension 8 .3 0 10.0% 9.1%
A sth m a 0.0% 2 0 .0% 9.1%
P reviou s T B 16.7% 0.0% 9.1%
P reviou s m alaria 8.3% 10.0% 9.1%
D ia b etes m ellitu s 8.3% 0.0% 4.5%
Isch aem ic  heart 
d isea se
8 .3% 0.0% 4.5%
C hronic kidney  
d isea se
0 .0% 10.0% 4.5%
E p ilep sy 0 .0% 10.0% 4.5%
P reviou s m alaria &  
E p ilep sy
0 .0% 10.0% 4.5%
H yp erten sion  &  
B en ign  prostatic  
hypertrophy
8.3% 0.0% 4.5%
Inotropes
n 4 0 52 92
0 .3 3 7Yes 6 7 .5% 57.7% 62.0%
N o 3 2 .5% 4 2 .3 % 38.0%
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n 4 0 52 92
R enal support Y es 52 .5% 59.6% 5 6 .5% 0 .4 9 5
N o 4 7 .5% 4 0 .4% 4 3 .5%
n 4 0 52 92
M echan ica l
ventila tion
Y es 50 .0% 2 6 .9% 3 7 .0% 0 .0 2 3
N o 50.0% 73.1% 6 3 .0%
n 17 11 28
Seizu res 4 1 .2% 3 6 .4% 3 9 .3%
D ro w sy 17.6% 9.1% 14.3%
Pulm onary ed em a 0.0% 18.2% 7.1%
V ision  lo ss 5.9% 0.0% 3.6%
S p eech  d e fect 0 .0% 9.1% 3.6%
N eu r o lo g ic a l
c o m p lica tio n s
P sy ch o sis 5.9% 0.0% 3.6%
0 .3 5 7
A R D S 11.8% 0.0% 7.1%
C o n fu sio n 0 .0% 9.1% 3.6%
S p len ic  infarcts 5.9% 0.0% 3.6%
P rolonged  Q T / 
card iac arrest
5.9% 9.1% 7.1%
U p per G IT  b leed in g 0 .0% 9.1% 3.6%
H y p o g ly ca e m ic
e p iso d e s
5.9% 0.0% 3.6%
N 4 0 52 92
L ength o f  stay
<5 days 4 5 .0% 4 6 .2% 4 5 .7%
0 .7 3 8
E xactly  5 days 12.5% 7.7% 9.8%
>  5 days 4 2 .5% 4 6 .2% 4 4 .6%
N 3 9 52 91
O u tcom e D ischarge 84 .6% 9 2 .3% 89.0% 0 .2 4 6
D eath 15.4% 7.7% 11.0%
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Table 1: Chi-square test for association between drug administered and several categorical 
variables
Table 2: Differences between the mean for patients on quinine vs those on artesunate
Variable n Quinine Artesunate Total T
P-value (2- 
tailed)
Age 91 36.23 40.45 38.59 -1.825 0.071
CD4 Count in cells/mm3 15 200.00 217.17 213.73 -0.161 0.875
Duration of inotropes 
treatment in days 35 4.62 3.50 3.91
0.812 0.423
Duration of renal support 
in days 51 6.05 6.60 6.37
-0.347 0.730
Mechanical ventilation 
duration in days 34 5.55 6.00 5.74 -0.240
0.812
GCS on admission 92 11.65 12.44 12.10 -1.039 0.302
GCS on discharge 83 14.91 14.16 14.47 1.779 0.081
Parasite count in 
percentages 75 12.57% 14.90% 13.91% -0.818 0.416
Lactate level in mmol/1 85 5.23 4.37 4.76 1.066 0.291
Bicarbonate level in 
mmol/1 92 17.20 18.49 17.93 -1.179
0.241
Heamoglobin level in g/dl 92 8.47 8.96 8.75 -0.801 0.425
Blood glucose level in 
mmol/1 87 5.69 6.41 6.09 -0.531 0.596
Creatinine level in mcmol/1 92 300.35 390.04 351.04 -1.329 0.187
APACHE II SCORE points 92 20.85 19.62 20.15 0.882 0.380
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Table 2: Independent samples t-test for difference between the mean for patients on quinine compared to 
those on artesunate
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CHAPTER 3: APPENDICES
3.1 Data Collection Sheet
Study no:
Age:
Gender:
Date of admission:
Date of discharge/death:
Drug administered (quinine/artesunate):
Travel history' 
o yes 
o no
HIV status 
o yes 
o no
Comorbidities 
o 1 
o 2
Inotropic support
o yes
o no j
If yes, for how many days?
Renal replacement 
o yes 
o no
If yes, for how many days?
Mechanical ventilation 
o yes 
o no
If yes, for how many days?
Neurological status
o GCS admission: (<11) (11-14) (15) 
o GCS discharge: (<11) (11-14) (15)
Length of stay in ICU: (>5days) (<5days)
Parasite count on admission in percentages
Lactate on admission in mmol/l
Bicarbonate on admission in mmol/l
Haemoglobin level on admission in g/dl
HGT level on admission in mmol
Creatinine in mcmol/l on admission
APACHE II SCORE on admission
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3.2 APACHE Score Sheet
Physiologic
Variable + 4 + 3 + 2 +  1 0 + 1 + 2 + 3 + 4
T e m p e r a tu r e  -  
r e c ta l  f C )
£41 39-40.9 38.5-38.9 36-38.4 34-35.9 32-33.9 30-31.9 <29.9
M e a n  A r te r ia l  
P r e ssu r e  ( c m  H»)
£160 130-159 110-129 70-109 50-69 <49
H e a r t  R a te £180' 140-179 110-139 70-109 55-69 40-54 <39
R esp ira to rs- R a te
(nonventilaled or 
ventilated)
£50 35-49 25-34 12-24 10-11 6 9 <5
O x y g e n a tio n
(c u n H ')
a. F iO j> C ,5 isa  A-aDO:
b. F iO 2 < 0 ,5 is a P a O j
a £500 350-499 200-349 <200
b > 7 0 61-70 55-60 <55
A r te r ia l  p H > 7.7 7.6-7.69 7.5-7.59 7.33-7.49 7.25-7.32 7.15-7.24 <7.15
S eru m  S o d iu m
(n n n l . 'l l
£180 160-179 155-159 150-154 130-149 120-129 111-119 <110
S eru m  P o ta ss iu m
(m n o l 'l)
£ 7 6-6.9 5.5-5.9 3.5-5.4 3-3.4 2.5-2.9 <2.5
S eru m  C r ea tin in e
{ n e< il| Double poin t 
score for aorta ra ta l 
failure)
>3.5 2-3.4 1.5-1.9 0 .6 1 .4 <0.4
H e m a to c r it  (3i) >60 50-59.9 4 6 4 9 .9 3 0 4 5 .9 20-29.9 <20
W h ite  B lo o d  
C ou n t {it lOW-raci-')
>40 20-39.9 15-19.9 3-14.9 1-2.9 <1
G la sg o w -C o m a -  
S c a le  (GCS)
S cots -  15 m inus actual GC S
S eru m  H C O j
(vemjUi, r n n l ' l ,  lira i f  t o  
A B Cs’)
>52 41-51.9 32-40.9 22-31.9 18-21.9 15-17.9 <15
A  =  T o ta l  A cu te  
P h y s io lo g y  S co re  
A P S
Sum  o f  the 12 in d iv id u a l v ariab le  p o in t ;
B  =  A g e  P o in ts C  =  C h ro n ic  H e a lth  P o in ts
I f  th e  p a tie n t h a s  a h istory  o f  severe  organ  sy s tem  in su ffic ien cy  or is 
im m u n o c o m p r o m ise d  ass ign  p o in ts  a s  fo llow s:
a. Fornonoparativa o r  emergency po;toparativa patient; -  5 po in t;
b. F o r  elective poitoparative patien t; -  2  point-.
<44 year; 0  p o in t ;  
45-54 year; 2  p o iE ti 
55-64 year; 3 p o iE ti 
45-74 yean  5 p o in t ;  
£75 y e a s  6  poin t;
APACHE H Score -  Sum of A (APS points) + B (Age points) + C (Chronic Health points)
(From: Knaus WA. Draper EA. Waqner DP. Zimmerman J E. APACHE II: a severity of disease
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